Table 3.
Case series comparison
| Veritti, 2017 [31] | Giuseppe, 2018 [32] | Minnella, 2019 [33] | Current study | |
|---|---|---|---|---|
| Eyes | 23 | 18 | 8 | 15 |
| Age (years) | 67.7 | 65 | 68.7 | 68 |
| Glucose mg/dL | - | < 250 | - | < 250 |
| HbA1c % | < 7.3 | < 9 | - | - |
| Baseline lens | - | - | 7 phakic | 6 phakic |
| Naïve/chronic | 9/14 | 12/6 | 3/5 | 0/23 |
| Previous tx | No steroids in the last 6 mo | None in the last 3 mo | None in the last 6 mo | At least 3 continuous antiVEGF |
| OCT | Cirrus, Zeiss | Cirrus, Zeiss | Heidelberg, Spectralis | Heidelberg, Spectralis |
| Evaluation | ||||
| Hours | - | 1,3 | 3 | 2,3 |
| Days | 1,2,3,7,14,21 | 3,7 | 1,7 | 1,7 |
| Months | 1,2,3 | 1 | 1,3 | 1 |
| BCVA mean change | 1.52 logMAR at 3 mo | 0.14 logMAR at 1 mo | 1.52 logMAR at 3 mo | 0.27 logMAR at 1 mo |
| CRT mean change (µm) | -256 | -225 | -183.9 | -195.93 |
BCVA Best-corrected visual acuity, CRT Central retinal thickness